{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"160"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"189"},{"groupId":"OG003","value":"191"}],"units":"Participants"}],"description":"SRE is defined as new fractures \\[including vertebral compression fractures\\], irradiation of or surgery on bone, or spinal cord compression.","groups":[{"description":"Participants who were randomly assigned to receive placebo matching capsule single oral dose on Days 1, 8 and 15 along with standard regimen of LenDex (lenalidomide 25 mg capsules orally on Days 1-21 and dexamethasone 40 mg tablets orally on Days 1, 8, 15 and 22) up to 18 cycles (each cycle was of 28 days).","id":"OG000","title":"Placebo + LenDex (Exposure Up to 18 Cycles)"},{"description":"Participants who were randomly assigned to receive Ixazomib 4.0 mg capsule single oral dose on Days 1, 8 and 15 along with standard regimen of LenDex (lenalidomide 25 mg capsules orally on Days 1-21 and dexamethasone 40 mg tablets orally on Days 1, 8, 15 and 22) up to 18 cycles (each cycle was of 28 days).","id":"OG001","title":"Ixazomib+ LenDex (Exposure Up to 18 Cycles)"},{"description":"Participants who were randomly assigned to receive placebo matching capsule single oral dose on Days 1, 8 and 15 along with standard regimen of LenDex (lenalidomide 25 mg capsules orally on Days 1-21 and dexamethasone 40 mg tablets orally on Days 1, 8, 15 and 22) up to 18 cycles (each cycle was of 28 days). Following Cycle 18, participants received 3.0 mg ixazomib placebo matching capsule as single oral dose on Days 1, 8 and 15 along with lenalidomide 10 mg capsules orally on Days 1-21 in each 28-day cycle until progressive disease or unacceptable toxicity, whichever comes first up to end of study (up to approximately 109 months).","id":"OG002","title":"Placebo + LenDex (Exposure ≥19 Cycles)"},{"description":"Participants who were randomly assigned to receive Ixazomib 4.0 mg placebo matching capsule single oral dose on Days 1, 8 and 15 along with standard regimen of LenDex (lenalidomide 25 mg capsules orally on Days 1-21 and dexamethasone 40 mg tablets orally on Days 1, 8, 15 and 22) up to 18 cycles (each cycle was of 28 days). Following Cycle 18, participants received 3.0 mg ixazomib capsule as single oral dose on Days 1, 8 and 15 along with lenalidomide 10 mg capsules orally on Days 1-21 in each 28-day cycle until progressive disease or unacceptable toxicity, whichever comes first up to end of study (up to approximately 109 months).","id":"OG003","title":"Ixazomib + LenDex (Exposure ≥19 Cycles)"}],"paramType":"NUMBER","populationDescription":"Safety population is defined as all participants who receive at least 1 dose of any study drug. Data for safety is summarized as per the duration of exposure to study treatment (exposure up to 18 cycles; exposure ≥19 cycles).","reportingStatus":"POSTED","timeFrame":"From the date of randomization through 30 days after the last dose of study drug up to end of study (up to approximately 9 years)","title":"Percentage of Participants With New or Worsening of Existing Skeletal-related Events (SREs)","type":"SECONDARY","unitOfMeasure":"percentage of partcipants"}